KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02162 KEYMED BIO-B

Market Closed 03-20 16:08:48

51.000

-1.150

-2.21%

High53.450	Low51.000	Vol1.01M
Open51.200	D1 Closing52.150	Amplitude4.70%
Mkt Cap15.25B	Tradable Cap15.25B	Total Shares299.00M
T/O52.43M	T/O Rate0.34%	Tradable Shares299.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"KEYMED BIO-B","latestPrice":51,"timestamp":1773994128002,"preClose":52.15,"halted":0,"volume":1013500,"delay":0,"changeRate":-0.02205177372962605,"floatShares":299000000,"shares":299000000,"eps":-1.966966,"marketStatus":"Market Closed","change":-1.15,"latestTime":"03-20 16:08:48","open":51.2,"high":53.45,"low":51,"amount":52428250,"amplitude":0.04698,"askPrice":51.2,"askSize":500,"bidPrice":51,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-0.945,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774229400000},"marketStatusCode":7,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":52.15,"openAndCloseTimeList":[[1773970200000,1773979200000],[1773982800000,1773993600000]],"volumeRatio":0.7822923892375495,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"2620963044","title":"Assessing Keymed Biosciences (SEHK:2162) Valuation After CMG901 Phase III Milestone With AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2620963044","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620963044?lang=en_us&edition=fundamental","pubTime":"2026-03-17 01:18","pubTimestamp":1773681497,"startTime":"0","endTime":"0","summary":"Keymed Biosciences (SEHK:2162) is back in focus after partner AstraZeneca began a Phase III trial of CMG901 in advanced gastric and related cancers, triggering a US$45 million milestone payment to the group.\nSee our latest analysis for Keymed Biosciences.\nThe CMG901 Phase III update comes after a strong 1 year total shareholder return of 50.97%. Shorter term share price momentum is steadier, with a 7 day share price return of 6.36% around the HK$54.35 level.\nIf you are looking for other...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/assessing-keymed-biosciences-sehk2162-valuation-after-cmg901","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/assessing-keymed-biosciences-sehk2162-valuation-after-cmg901","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4134","DCF","BK1583","02162","BK1587","III","BK1574","BK1161"],"gpt_icon":0},{"id":"1136749979","title":"Keymed Biosciences (02162) Schedules 26 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1136749979","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136749979?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:21","pubTimestamp":1773652899,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. (Stock Code: 02162) announced that its board of directors will convene on 26 March 2026. The agenda includes: • Reviewing and approving the consolidated financial results for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"gpt_icon":0},{"id":"2619245537","title":"Keymed Biosciences to Hold Board Meeting to Approve Annual Results and Consider Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2619245537","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619245537?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:56","pubTimestamp":1773651388,"startTime":"0","endTime":"0","summary":"Keymed Biosciences will hold a board meeting on March 26, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL35RFlP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02162","BK1587","BK1583","BK1161"],"gpt_icon":0},{"id":"1195864950","title":"Hong Kong Stock Movement | KEYMED BIO-B (02162) Rises Over 3% Again, Receives $45 Million Milestone Payment from AstraZeneca for CMG901","url":"https://stock-news.laohu8.com/highlight/detail?id=1195864950","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195864950?lang=en_us&edition=fundamental","pubTime":"2026-03-12 10:08","pubTimestamp":1773281284,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) saw its shares rise more than 3% again. At the time of writing, the stock was up 2.21%, trading at HK$55.5, with a turnover of HK$7.5096 million. On the news front, KEYMED BIO...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4588","VXUS","LU0289739699.SGD","IE00B3T34201.USD","LU2417539215.USD","LU0058720904.USD","BK4568","BK1583","LU0889565916.HKD","BK4585","LU0320765992.SGD","BK4007","LU2456880835.USD","LU2236285917.USD","02162","BK1574","LU0109394709.USD","LU2462157665.USD","AZN","BK1587","LU1829250122.USD"],"gpt_icon":0},{"id":"2618518999","title":"Lepu Biopharma Says AstraZeneca Begins Phase 3 Trial of CMG901 Cancer Therapy; Shares Jump 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618518999","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618518999?lang=en_us&edition=fundamental","pubTime":"2026-03-11 10:08","pubTimestamp":1773194916,"startTime":"0","endTime":"0","summary":"Lepu Biopharma Co  said AstraZeneca has initiated a Phase 3 clinical study of its antibody-drug conjugate candidate CMG901, triggering a milestone payment of $45 million under their collaboration agreement, according to a Wednesday Hong Kong bourse filing.The trial is evaluating sonesitatug vedotin  in combination with capecitabine, with or without rilvegostomig, for first-line treatment of Claudin 18.2-positive, HER2-negative advanced or metastatic gastric and related cancers.CMG901 was developed through KYM Biosciences, a joint venture between Lepu Biopharma and Keymed Biosciences .Lepu Biopharma's shares jumped nearly 7% in early-morning trade on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1587","02157","BK1583","02162","BK1161","BK1574"],"gpt_icon":0},{"id":"2618293920","title":"BRIEF-Keymed Biosciences Updates On Collaboration With Astrazeneca On Core Product CMG901 (AZD0901)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618293920","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618293920?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:28","pubTimestamp":1773138525,"startTime":"0","endTime":"0","summary":"BRIEF-Keymed Biosciences Updates On Collaboration With Astrazeneca On Core Product CMG901 March 10  - Keymed Biosciences Inc 2162.HK:UPDATE ON COLLABORATION WITH ASTRAZENECA ON CORE PRODUCT CMG901 ASTRAZENECA INITIATES PHASE III STUDY OF AZD0901 FOR ADVANCED GASTRIC CANCERFurther company coverage: 2162.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nFWN3ZY01X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2539964713.USD","LU0640478417.SGD","LU0122379950.USD","LU0496365809.HKD","LU1267930573.SGD","IE00B3T34201.USD","LU1267930813.SGD","LU1061106388.HKD","LU1989772923.USD","IE0034235188.USD","LU2114397693.USD","LU0211327993.USD","LU0889565080.SGD","LU2293690082.USD","LU0203347892.USD","BK5011","LU1481600234.SGD","LU0211326839.USD","LU2091194634.USD","LU0345777659.USD","LU1078025761.USD","LU0128525689.USD","LU0077335932.USD","AZN.UK","LU0949170426.SGD","LU1019632923.USD","LU0432979614.USD","LU0969580561.USD","LU0047473722.EUR","LU0949170772.SGD","BK1583","LU1261432733.SGD","LU2112291526.USD","LU0997586432.USD","LU1019634622.SGD","LU1015430645.USD","LU1153585028.USD","LU0499090636.EUR","LU1064927863.SGD","LU0882574055.USD","LU0553294199.USD","LU2468319806.SGD","LU1170363599.USD","LU0857590862.USD","LU0289739699.SGD","LU0792757196.USD","LU0889566641.SGD","02162","SG9999013999.USD","03165"],"gpt_icon":0},{"id":"1121253893","title":"KEYMED BIO-B (02162) Announces AstraZeneca Initiates Clinical Trial for CMG901 (AZD0901) with First Patient Dosed","url":"https://stock-news.laohu8.com/highlight/detail?id=1121253893","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121253893?lang=en_us&edition=fundamental","pubTime":"2026-03-10 17:10","pubTimestamp":1773133838,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) has announced an update regarding its collaboration with AstraZeneca AB on the core product CMG901, also known as sonesitatug vedotin or AZD0901. As of the date of this...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1587","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2618938054","title":"KeyMed Biosciences Inc - Update on Collaboration With AstraZeneca on Core Product Cmg901 (Azd0901)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618938054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618938054?lang=en_us&edition=fundamental","pubTime":"2026-03-10 17:00","pubTimestamp":1773133210,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nFWN3ZY01X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02162","BK1587","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2618380689","title":"KeyMed Biosciences Inc - AstraZeneca Initiates Phase Iii Study of Azd0901 for Advanced Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618380689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618380689?lang=en_us&edition=fundamental","pubTime":"2026-03-10 17:00","pubTimestamp":1773133210,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nFWN3ZY01X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1019634622.SGD","LU1880407132.USD","LU0211327993.USD","LU0949170426.SGD","IE0002141913.USD","LU0266013472.USD","LU0957799991.USD","BK1161","IE0009355771.USD","IE00B4R5TH58.HKD","LU0708994859.HKD","LU1487256676.USD","LU1291159041.SGD","LU1078025761.USD","LU2279689827.SGD","LU1104425308.USD","LU0972486137.USD","LU0310799852.SGD","LU2108987350.USD","LU0857590862.USD","LU0823416689.USD","LU0545039389.USD","LU0976567544.SGD","LU0738911758.USD","LU2293690082.USD","LU1989772840.SGD","LU0827474353.SGD","LU1046234339.USD","LU0887340254.USD","IE00BJJMRZ35.SGD","LU1119994496.HKD","LU0557290698.USD","03165","AZN.UK","LU0203345920.USD","LU1496350171.SGD","LU2468319806.SGD","LU0345777659.USD","LU0058720904.USD","LU0661504455.SGD","IE00BKPKM643.USD","LU1267930813.SGD","LU1814569148.SGD","LU1015430645.USD","LU0963555726.SGD","02162","LU0496365809.HKD","LU1267930227.SGD","SG9999001176.USD","LU2091194634.USD"],"gpt_icon":0},{"id":"2618251938","title":"Keymed Biosciences receives USD45 million CMG901 milestone payment from AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2618251938","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618251938?lang=en_us&edition=fundamental","pubTime":"2026-03-10 16:59","pubTimestamp":1773133192,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL1p47WD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772923.USD","LU1046234339.USD","LU0310800379.SGD","LU2023251221.USD","IE0002141913.USD","02157","LU0058720904.USD","LU0114720955.EUR","LU0957799991.USD","LU0203347892.USD","LU0345777659.USD","LU1153585028.USD","LU2089283258.USD","LU0526926950.USD","SG9999001176.USD","BK1574","IE00B3T34201.USD","LU1989771016.USD","LU0029864427.USD","LU0211328371.USD","03165","LU1015430645.USD","LU0203345920.USD","LU1301847155.USD","LU0963555726.SGD","LU1170363599.USD","AZN.UK","LU2108987350.USD","LU0557290698.USD","LU0738911758.USD","IE0034235188.USD","LU1880407215.USD","LU0823416689.USD","LU0784384876.USD","LU0784385840.USD","LU2539964713.USD","LU1104425308.USD","LU2293690082.USD","LU1989772840.SGD","LU0889566641.SGD","LU0949170426.SGD","LU2091194634.USD","LU2112291526.USD","02162","LU2089284900.SGD","LU0889565080.SGD","LU0661504455.SGD","SG9999001176.SGD","IE0009355771.USD","LU1880407132.USD"],"gpt_icon":0},{"id":"1115207358","title":"Biopharma Stocks Rally as Sector Gains Strategic \"Emerging Pillar\" Status","url":"https://stock-news.laohu8.com/highlight/detail?id=1115207358","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115207358?lang=en_us&edition=fundamental","pubTime":"2026-03-06 10:14","pubTimestamp":1772763264,"startTime":"0","endTime":"0","summary":"Innovative drug stocks strengthened during the morning session. At the time of writing, HUTCHMED (00013) rose 9.02% to HK$22.96; 3SBIO (01530) increased 8.41% to HK$21.4; HENGRUI PHARMA (01276)...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","BK1588","BK1593","LU2543165471.USD","LU0455707207.USD","BK1583","01801","LU2097828714.EUR","LU1023057109.AUD","BK4588","BK1191","HK0000165453.HKD","LABU","LU2097828805.USD","LU2328871848.SGD","LU0359201885.HKD","VXUS","161726","LU2488822045.USD","BK1587","LU0359202008.SGD","02162","LU1969619763.USD","LU2097828631.EUR","LU0502904849.HKD","BK4585","LU2242644610.SGD","159992","LU0359201612.USD","00013","BK1161","BK1589","LU2097828474.EUR","VT","01276","BK1574","06978","399441","LU2097828557.USD"],"gpt_icon":0},{"id":"1180167941","title":"Keymed Biosciences Inc. (02162): February 2026 Monthly Securities Movement Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1180167941","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180167941?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:49","pubTimestamp":1772444953,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. announced that as of February 28, 2026, authorized share capital remained at 500.00 million shares, each with a par value of USD 0.0001, totaling USD 0.05 million in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"gpt_icon":0},{"id":"2608810669","title":"Pinning Down Keymed Biosciences Inc.'s (HKG:2162) P/S Is Difficult Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2608810669","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608810669?lang=en_us&edition=fundamental","pubTime":"2026-02-03 07:37","pubTimestamp":1770075447,"startTime":"0","endTime":"0","summary":"There wouldn't be many who think Keymed Biosciences Inc.'s ( HKG:2162 ) price-to-sales (or \"P/S\") ratio of 16.2x is...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/pinning-down-keymed-biosciences-incs-hkg2162-ps-is-difficult","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/pinning-down-keymed-biosciences-incs-hkg2162-ps-is-difficult","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1587","BK1574","02162","BK1583","BK1161"],"gpt_icon":0},{"id":"1189199449","title":"Keymed Biosciences Inc. (02162) Announces January 2026 Monthly Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1189199449","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189199449?lang=en_us&edition=fundamental","pubTime":"2026-02-02 16:51","pubTimestamp":1770022271,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. (02162) has published its January 2026 monthly return, confirming an authorized share capital of 500,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"gpt_icon":0},{"id":"1197938528","title":"Hong Kong Stocks Movement | KEYMED BIO-B (02162) Rises Nearly 3%, Self-Developed BCMA×CD3 Bispecific Antibody CM336 Granted FTD Designation by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1197938528","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197938528?lang=en_us&edition=fundamental","pubTime":"2026-01-27 11:28","pubTimestamp":1769484502,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) rose nearly 3%. As of the time of writing, the stock was up 2.24%, trading at HK$57, with a turnover of HK$19.7112 million. On the news front, according to an announcement on...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02162","BK1583","BK1161","BK1587"],"gpt_icon":0},{"id":"1176519224","title":"HK Stock Movement | KEYMED BIO-B (02162) Opens Over 4% Higher as Sprifermin Injection Included in National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1176519224","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176519224?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:30","pubTimestamp":1765157433,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) opened over 4% higher, rising 4.23% to HK$61.6 by the time of writing, with a turnover of HK$1.3244 million. On December 7, KEYMED BIO announced that its self-developed Class 1...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","BK1587","BK1574","02162"],"gpt_icon":0},{"id":"1199403427","title":"Keymed Biosciences Inc. (02162) Reports Steady Share Capital for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1199403427","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199403427?lang=en_us&edition=fundamental","pubTime":"2025-12-01 18:21","pubTimestamp":1764584466,"startTime":"0","endTime":"0","summary":"Keymed Biosciences Inc. (02162) released its monthly return on movements in securities for the period ended 30 November 2025. According to the announcement, the company’s authorized share capital...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"gpt_icon":0},{"id":"1132878901","title":"HK Stock Movement | KEYMED BIO-B (02162) Rises Over 4% as Institutions Bullish on CM512's Global Value; Spesolimab Sales Expected to Accelerate Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1132878901","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132878901?lang=en_us&edition=fundamental","pubTime":"2025-11-25 11:32","pubTimestamp":1764041537,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) surged over 4%, reaching HK$59.95 by the time of writing, with a trading volume of HK$31.28 million. The company recently announced that its self-developed CM512, the world's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1583","BK1574","BK1161","BK1587"],"gpt_icon":0},{"id":"1171499670","title":"China Post Securities: Rapid Clinical Progress in Autoimmune Bispecific Antibodies, Sustained Trading and R&D Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1171499670","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171499670?lang=en_us&edition=fundamental","pubTime":"2025-11-18 11:22","pubTimestamp":1763436142,"startTime":"0","endTime":"0","summary":"China Post Securities released a research report stating that bispecific antibodies (BsAbs) in the autoimmune field have the potential to reshape the current treatment landscape, particularly in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","161027","BK1161","02162","BK1587"],"gpt_icon":0},{"id":"1181014719","title":"HK Stock Connect Shareholding Changes | November 12","url":"https://stock-news.laohu8.com/highlight/detail?id=1181014719","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181014719?lang=en_us&edition=fundamental","pubTime":"2025-11-12 08:38","pubTimestamp":1762907908,"startTime":"0","endTime":"0","summary":"As of November 11, 2025, data shows that HAO TIAN INTL (01341), REPT BATTERO (00666), and CTG DUTY-FREE (01880) recorded the largest increases in Stock Connect shareholding ratios, rising by 1.72%,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06616","02465","09885","01282","02587","BK1582","BK1564","00119","IE00BZ08YR35.GBP","SG9999006597.SGD","01773","03678","BK1183","BK1504","02837","BK1197","01347","00763","BK1529","BK1148","BK1505","BK1568","BK1138","SG9999003461.SGD","02402","IE0034224299.USD","01341","BK1235","02648","00189","03759","BK1596","00956","BK1506","BK1141","BK1589","LU1983299162.USD","01053","00666","01880","BK1513","BK1567","06865","BK1161","01072","00874","BK1607","BK1205","LU2543165471.USD","00568","BK1170","LU0326950275.SGD","02727","BK1125","BK1202","03931","BK1515","06613","03866","IE00B29SXG58.USD","LU1831875114.USD","02255","BK1588","02865","01709","HK0000252152.HKD","BK1546","00095","IE00BZ08YT58.USD","00525","BK1576","BK1518","LU0588546209.SGD","LU2488822045.USD","BK1558","BK1613","BK1144","BK1587","02068","BK1606","01877","BK1511","IE00BZ08YS42.EUR","06955","LU0708995583.HKD","HK0000500386.USD","BK1166","02533","09606","BK1236","BK1171","BK1116","00968","00902","03347","BK1149","BK1554","02828","06869","BK1516","06680","BK1590","BK1241","BK1521","02631","09696","09688","BK1129","BK1191","BK1163","LU1720050803.USD","BK1169","BK1560","LU0320764599.SGD","BK1614","06682","LU1794554557.SGD","02050","BK1109","LU0348825331.USD","02208","BK1237","BK1147","BK1610","LU1969619763.USD","SG9999014674.SGD","BK1240","BK1556","02382","LU0307460666.USD","09995","BK1583","BK1594","BK1219","BK1526","LU0417516902.SGD","02162","LU2328871848.SGD","BK1500","BK1522","BK1555","HK0000252160.HKD","00187","BK1608","BK1225","LU0348735423.USD","02013","MCHmain","LU0052750758.USD","02562","BK1523","01071","BK1503","03800","LU0417516738.SGD","BK1530","BK1224","BK1110","BK1574","LU1211504680.USD","BK1228"],"gpt_icon":1}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0304},{"period":"1month","weight":-0.0556},{"period":"3month","weight":-0.0811},{"period":"6month","weight":-0.2926},{"period":"1year","weight":0.301},{"period":"ytd","weight":-0.0458}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0535},{"period":"3month","weight":-0.0161},{"period":"6month","weight":-0.0478},{"period":"1year","weight":0.0437},{"period":"ytd","weight":-0.0138}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.2,"avgChangeRate":-0.018146},{"month":4,"riseRate":1,"avgChangeRate":0.037917},{"month":5,"riseRate":0.25,"avgChangeRate":-0.097555},{"month":6,"riseRate":1,"avgChangeRate":0.124436},{"month":7,"riseRate":0.5,"avgChangeRate":0.132155},{"month":8,"riseRate":0.6,"avgChangeRate":0.038036},{"month":9,"riseRate":0.8,"avgChangeRate":0.042936},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"KEYMED BIO-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"KEYMED BIO-B,02162,KEYMED BIO-B股票,KEYMED BIO-B股票老虎,KEYMED BIO-B股票老虎国际,KEYMED BIO-B行情,KEYMED BIO-B股票行情,KEYMED BIO-B股价,KEYMED BIO-B股市,KEYMED BIO-B股票价格,KEYMED BIO-B股票交易,KEYMED BIO-B股票购买,KEYMED BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}